Matthews DR, et al. – In the Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of T2DM (VERIFY) trial—a randomized, double-blind, parallel-group study involving patients with newly diagnosed type 2 diabetes mellitus (T2DM) in 254 centers across 34 countries—researchers ascertained the glycemic durability of an early combination therapy with vildagliptin and metformin vs sequential metformin monotherapy. Of the 4,524 people screened, 2,001 qualified persons were randomized to either the early combination treatment group (n = 998) or the initial metformin monotherapy group (n = 1,003). Compared with the prevailing standard-of-care of initial metformin monotherapy, early intervention with combination therapy of vildagliptin plus metformin offered greater and enduring long-term benefits in individuals with newly diagnosed T2DM.